TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06508268

Intervention type: BEHAVIORAL
Intervention: Jamar hand dynamometer
Description: Hand grip strength will be assessed by a Jamar hand dynamometer

Intervention type: BEHAVIORAL
Intervention: Jamar hand dynamometer
Description: Hand grip strength will be assessed by a Jamar hand dynamometer

Intervention type: BEHAVIORAL
Intervention: Picture description task
Description: Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)

Intervention type: BEHAVIORAL
Intervention: Picture description task
Description: Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)

Intervention type: BEHAVIORAL
Intervention: Picture description task
Description: Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)

Intervention type: BEHAVIORAL
Intervention: Picture description task
Description: Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)

Intervention type: BEHAVIORAL
Intervention: Autobiographical semi-structured conversation
Description: Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation

Intervention type: BEHAVIORAL
Intervention: Autobiographical semi-structured conversation
Description: Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation

Intervention type: BEHAVIORAL
Intervention: Autobiographical semi-structured conversation
Description: Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation

Intervention type: BEHAVIORAL
Intervention: Autobiographical semi-structured conversation
Description: Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
Study: NCT06496789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab+SOX
Description: Serplulimab+Oxaliplatin+S1
Study: NCT05635227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: See description of arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride (0.9%)
Description: See description of arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 MG
Description: Olanzapine tablet pre-hidden in capsule identical to the placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: capsule identical to capsule containing olanzapine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-targeted hemodynamic management
Description: See description of arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-targeted hemodynamic management
Description: See description of arms

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tidal-volume ventilation
Description: See description of arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ventilation
Description: See description of arms
Study: NCT04663256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation group
Description: Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
Study: NCT05549206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
Description: 50μg/dose
Study: NCT05720364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), fasted group
Description: TP-05 (lotilaner oral), fasted group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), high-fat group
Description: TP-05 (lotilaner oral), high-fat group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), low-fat group
Description: TP-05 (lotilaner oral), low-fat group
Study: NCT05424263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Acetate Oral Solution
Description: Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate Oral Suspension
Description: Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
Study: NCT05238259

Intervention type: DEVICE
Group type: OTHER
Intervention: kinesiotaping
Description: Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.

Intervention type: DEVICE
Group type: OTHER
Intervention: wrist wheel
Description: Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
Study: NCT05549206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
Description: 100μg/dose
Study: NCT05642143

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorbtiometry scan
Description: Evaluation of body composition and bone mass density

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorbtiometry scan
Description: Evaluation of body composition and bone mass density
Study: NCT05549206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05642143

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorbtiometry scan
Description: Evaluation of body composition and bone mass density

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution peripheral quantitative computed tomography
Description: High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution peripheral quantitative computed tomography
Description: High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution peripheral quantitative computed tomography
Description: High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microindentation
Description: Measures Bone Material Strength Index (BMSi) of cortical bone.
Study: NCT05715008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
Study: NCT05066373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 capsule A
Description: EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 capsule B
Description: EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 tablet
Description: EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
Study: NCT06413342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
Study: NCT05783115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion
Description: transverse bone transport with bone marrow cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial Transportation
Description: transverse bone transport
Study: NCT05652998

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. albicans antigen
Description: a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous PRP
Description: patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
Study: NCT05424458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Implant Treatment
Description: Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
Study: NCT06350916

Intervention type: BEHAVIORAL
Intervention: SeamlessMD® Mobile Application
Description: Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
Study: NCT05002088

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Replacement
Description: Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Replacement
Description: Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
Study: NCT06007833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy and Rehabilitation Modalities
Description: In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
Study: NCT05520125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells enriched by extracellular vesicles
Description: Mesenchymal stem cells enriched by extracellular vesicles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of bone defects
Description: Standard surgical treatment of bone defects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment of bone defects
Description: Standard surgical treatment of bone defects
Study: NCT06582940

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-guided adaptive SRT
Description: MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SRT
Description: Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
Study: NCT01368315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 application
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention to one out of four test fields marked on the patient's back.
Study: NCT05191537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Natural Apophyseal Glides
Description: The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shoulder Mobilization with arm movement
Description: The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
Study: NCT05298761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
Study: NCT06239857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural pulsed radiofrequency
Description: The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
Study: NCT05404334

Intervention type: DIAGNOSTIC_TEST
Intervention: Androgen receptor status and BRCA mutation
Description: Androgen receptor status by IHC and germ line BRCA mutation

Intervention type: DIAGNOSTIC_TEST
Intervention: Androgen receptor status and BRCA mutation
Description: Androgen receptor status by IHC and germ line BRCA mutation
Study: NCT05194098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil
Description: Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM (inactive) TMS stimulation
Description: Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
Study: NCT05762692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation device
Description: The patients included will be oxygenated by HFNO device during the operation
Study: NCT06551181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo is administered intramuscularly at Day 1.
Study: NCT05976022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: 2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
Study: NCT05117619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME for Us
Description: HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control condition
Description: The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
Study: NCT04934345

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluid challenge
Description: The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
Study: NCT05417945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JensClip transcatheter valve repair system
Description: Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.
Study: NCT05959330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Tension Technique(ulnar, median, radial)
Description: Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Slider Technique (ulnar, median, radial)
Description: Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)
Description: Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment